Welcome to our dedicated page for HCA Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Healthcare, Inc. reported that it issued a press release covering its results for the third quarter ended September 30, 2025, and declared a quarterly cash dividend.
The Board approved a $0.72 per-share dividend on common stock, payable on December 29, 2025 to shareholders of record at the close of business on December 15, 2025. The Q3 results press release is included as Exhibit 99.1.
HCA Healthcare, Inc. (HCA) disclosure shows a proposed sale of 3,836 common shares through Merrill Lynch on the New York Stock Exchange with an aggregate market value of $1,606,670.20 and an approximate sale date of 09/08/2025. The shares were acquired on 09/04/2025 via exercises of Stock Appreciation Rights (2,782 and 1,054 shares) and payment was recorded as compensatory.
The filer reports no securities sold in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information. Several identifying fields for the filer and issuer (CIK, names, addresses) are not populated in the provided content.
Michael S. Cuffe, Executive Vice President and Chief Clinical Officer of HCA Healthcare (HCA), reported transactions under a Rule 10b5-1 plan adopted May 6, 2025. On 09/04/2025 he exercised 10,920 stock appreciation rights at an exercise price tied to $173.12 and those underlying 10,920 common shares were issued. On 09/04/2025 he sold 7,084 shares at $411.59 and on 09/08/2025 he sold 3,836 shares at $418.84, which together equal the 10,920 shares from the SAR exercise. Following these transactions his reported beneficial ownership stood at 31,502.9017 shares, which includes 2,595.9017 shares held under the company's employee stock purchase plans. The SARs vested in four equal annual installments beginning February 3, 2022.
HCA Healthcare has filed a Form S-8 to register an additional 13,150,000 shares of common stock ($0.01 par value) under its 2020 Stock Incentive Plan for Key Employees. This amendment to the plan became effective April 24, 2025.
Key details of the filing:
- Registration is for additional shares authorized under the amended 2020 Stock Plan
- Company is classified as a large accelerated filer
- Filing incorporates by reference multiple documents including the 2024 Annual Report, Q1 2025 Quarterly Report, and recent Current Reports
The filing includes executive signatures from key leadership including Samuel N. Hazen (CEO), Michael A. Marks (CFO), and Thomas F. Frist III (Chairman). This stock plan registration indicates HCA Healthcare's continued investment in employee compensation and retention through equity-based incentives.